Learn More
PURPOSE The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to the same regimen with(More)
The aim of our study was to evaluate the impact on time to progression (TTP) and overall survival (OS) of high-dose chemotherapy (HD-CT) over conventional CT in metastatic breast cancer patients.(More)
544 Background: CCI-779, a novel mTOR kinase inhibitor, is well tolerated and has shown antitumor activity in heavily pretreated patients (pts) with metastatic breast cancer (MBC). The combination of(More)